Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Jack Bodner is a partner in the firm’s Mergers and Acquisitions group. He has more than 25 years of experience in advising acquirors, targets, investors, boards of directors, special committees, and investment banks in domestic and cross-border negotiated and unsolicited mergers and acquisitions transactions.

Mr. Bodner’s practice also includes counseling clients on corporate and governance related matters, including compliance and disclosure issues, shareholder rights plans and proxy contests, and other defense and takeover measures. Mr. Bodner received his J.D. from New York University School of Law and his B.A., magna cum laude, from New York University.

  • IFM Therapeutics:
    • in the sale of IFM’s NLRP3 antagonist programs to Novartis for up to $1.275 billion;
    • in the sale of IFM’s STING and NLRP3 agonist programs to BMS for up to $1.3 billion; and
    • in a collaboration and option transaction with Novartis in connection with cGAS/STING-related immunotherapies, with an option value of up to $840 million.
  • China Grand Pharmaceutical and Healthcare Holding and Sirtex Medical US Holdings in connection with a $30 million strategic controlling investment in OncoSec Medical and in an exclusive license to develop, manufacture, and commercialize various OncoSec products.
  • Novo Nordisk:
    • in its acquisition of a manufacturing facility from Purdue Pharma; and
    • in its acquisition of a tropical disease Priority Review Voucher from Medicines Development for Global Health.
  • Astellas in its $384 million acquisition of Ocata Therapeutics, a biotechnology company specializing in the development of stem cell-based treatments in regenerative medicine.
  • Illumina, Inc.:
    • in its announced $1.2 billion acquisition of Pacific Biosciences;
    • in its up to $450 million acquisition of Verinata Health, Inc.;
    • in its acquisition of NextBio; and
    • in its creation of a joint venture with Warburg Pincus and Sutter Hill Ventures focused on accelerating consumer adoption of genomics.
  • SK Holdings and SK Biotek Co., Ltd., in the acquisition of a small molecule active pharmaceutical ingredient manufacturing facility from BMS.
  • Oxford Immunotec:
    • in its acquisition of Imugen, Inc.;
    • in its acquisition of Immunetics, Inc.; and
    • in its $170 million sale of its U.S. laboratory services business to Quest Diagnostics.
  • Reliance Industries Limited in its $75 million acquisition of Radisys Corporation.
  • Fiberon in its $470 million sale to Fortune Brands Home & Security.
  • GlaxoSmithKline in its the acquisition of ex-U.S. rights relating to the Quell wearable pain relief technology from with NeuroMetrix, Inc..
  • Famy Care Limited in the $750 million sale of its women's health business to Mylan Laboratories.
  • Oplink Communications in its $445 million sale to Koch Industries.
  • Metro Athletic Medicine & Fitness in the sale of its non-clinical assets to Pharos Capital. 
  • Lightbridge Communications, an independent global provider of network engineering services to the telecommunications industry, in its $240 million sale to Tech Mahindra.
  • The Walt Disney Company:
    • in its $5.3 billion acquisition of Fox Family Worldwide;
    • in its acquisition of Instafluence;
    • in its acquisition of India's UTV Software Communications Limited; and
    • in its acquisition of assets of The Jim Henson Company, Inc. (Muppets and Bear in the Big Blue House).
  • OptiSolar in the $400 million sale of its project development business to First Solar, Inc.
  • Asuragen in the sale of its miRInform® Thyroid and Pancreas test assets to Interpace Diagnostics, a subsidiary of PDI, Inc.
  • Assurant in its acquisition of Mobile Defense, a technology company focused on mobile device diagnostics and data processing for user assistance and predictive forecasting.
  • Broadridge Financial Solutions in its acquisition of technology assets of INVeSHARE to develop blockchain applications for Broadridge’s proxy business.
  • King Pharmaceuticals in its $3.6 billion merger with Pfizer.
  • Autogrill S.p.A. in the spin-off and sale of the U.S. airport retail concession business from HMSHost Corporation to World Duty Free Group.
  • Mainfreight Limited in its acquisition of Target Logistics.
  • Lottomatica S.p.A. in its $4.8 billion acquisition of GTECH Holdings Corporation, a publicly listed lottery and gaming technology company.
  • Financial Federal Corporation in its $738 merger with People’s United Financial.
  • B. Riley Financial in its acquisition of MK Capital Advisors.
  • Gannett Broadcasting in its formation and broadcasting of the Justice Network, a digital multicast channel devoted to law enforcement-related programming.
  • Faros Trading in the sale of a controlling interest to FXCM Inc.  
  • A U.S.-based medical devices company in its acquisition and related long-term license of a spinal device from a privately-held medical devices company, involving an upfront payment of cash together with a series of milestone payments.           
  • Trustmark Corporation in its sale of eight mutual fund portfolios of the Performance Funds Trust to Federated Investors Inc.
  • Gleacher & Company, Inc. in the sale of substantially all of the assets of its ClearPoint subsidiary to Homeward Residential, Inc., a wholly owned subsidiary of Ocwen Financial.
  • Saddle Gold in its sale to Premier Gold Mines.
  • UBS Securities LLC on the sale of a portfolio of interests in selected private equity funds to an investment firm.
  • Van Wagner in connection with Clear Channel’s acquisition of Van Wagner’s European billboard business.
  • Fiber Composites in its acquisition of Louisiana-Pacific Corporation's WeatherBest decking and railing business, and manufacturing and distribution facility in Meridian, Idaho.  
  • Metropolitan Intercollegiate Basketball Association in connection with the NCAA’s acquisition of the NIT.
  • Intergen (North America), Inc. in connection with Harbert Distressed Investment Master Fund, Ltd.’s acquisition of the Mayflower, Cottonwood & Redbud Projects.
  • LifePoint Hospitals in connection with LifePoint’s $1.7 billion acquisition of Province Healthcare Company.  
  • Burns, Philp & Company in the $1.35 billion sale of its yeast and bakery ingredient lines and Tone Brothers herbs and spices line to Associated British Food.
  • Special Committee of the Board of Directors of Covansys Corporation in connection with Fidelity Information Services Inc.’s $356 million acquisition of an interest in Covansys.
  • Special Committee of the Board of Directors of barnesandnoble.com inc. in its $513 million sale to Barnes & Noble, Inc.
  • Zimmer Holdings, Inc. in connection with its unsolicited $3.5 billion acquisition of Centerpulse AG and InCentive AG.
  • Triad Hospitals in connection with its $2.2 billion acquisition of Quorum Health Group.
  • Novartis Pharma AG in connection with its $1.6 billion acquisition of the pharmaceutical products Famvir® and Denavir® from SmithKline Beecham plc.
  • Chambers USA, Corporate/M&A (2016-2017) 
  • Legal 500 US, Energy: Renewable/Alternative (2016); M&A: Commercial Deals and Contracts (2016); M&A: Large Deals (2012-2014); Energy: Regulatory (2014)